American Heart Journal
Volume 158, Issue 1 , Pages 141-148.e1 , July 2009

Renal function, atherothrombosis extent, and outcomes in high-risk patients

  • Raphaelle L. Dumaine, MD

      Affiliations

    • Pitié-Salpêtrière University Hospital, Paris, France
    • ,
  • Gilles Montalescot, MD, PhD

      Affiliations

    • Pitié-Salpêtrière University Hospital, Paris, France
    • Corresponding Author InformationReprint requests: Gilles Montalescot, MD, PhD, Institut de Cardiologie, CHU Pitié-Salpêtrière, 47 boul de l'Hôpital, 75013 Paris, France.
    • ,
  • Ph. Gabriel Steg, MD

      Affiliations

    • Bichat-Claude Bernard University Hospital, Paris, France
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke University, Durham, NC
    • ,
  • Kim Eagle, MD

      Affiliations

    • University of Michigan Cardiovascular Center, Ann Arbor, MI
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA
    • ,
  • on behalf of the REACH Registry Investigators

Received 10 December 2008 ,Accepted 2 May 2009.

References 

  1. Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701
  2. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55
  3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  4. Dumaine R, Collet JP, Tanguy ML, et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol. 2004;94:1543–1547
  5. Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004;25:1998–2005
  6. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89:1003–1008
  7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  8. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.e1–786.e10
  9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  11. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  12. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–459
  13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  14. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  15. Tonelli M, Moye L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104
  16. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  17. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–1407
  18. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1–S153
  19. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207–S210

 See Appendix (available online) for a complete listing of REACH Registry Investigators.

PII: S0002-8703(09)00355-X

doi: 10.1016/j.ahj.2009.05.011

American Heart Journal
Volume 158, Issue 1 , Pages 141-148.e1 , July 2009

Article Tools

* Image Usage & Resolution